Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2018

View Archived Issues

Next-generation polymyxins could bring immunotherapy to antibiotics

New hSTING agonists presented as cancer immunotherapy agents

pAAV.CMV.miR204 shows protective effect on photoreceptors in models of inherited retinal disease

Researchers unveil NAXD gene as causative of a neurodegenerative disorder

Compound CAR T cells targeting CLL1 and CD33 in refractory acute myeloid leukemia: phase I results

First human data presented for prostate cancer imaging agent [68Ga]PSMA-093

Embryonic stem cells make helpful heart muscles

New mutations in SLC25A24 gene found to cause Fontaine syndrome

Pivotal phase III trial of Pixuvri in B-cell NHL does not meet primary endpoint

Promising interim data presented from phase I study of oral carbapenem SPR-994

Assembly Biosciences initiates phase IIa studies of ABI-H0731 for HBV

Codexis begins dosing in first-in-human study of CDX-6114 for PKU

Phase III trial of luspatercept in transfusion-dependent beta-thalassemia meets primary endpoint

Intrapulmonary penetration of ETX-2514SUL supports development for respiratory infections

MediciNova announces subgroup analyses from trial of MN-166 in ALS

Catabasis announces plans for phase III trial of edasalonexent in DMD

Bellus Health initiates phase I study of BLU-5937 for the treatment of chronic cough

Matinas collaborates with NINDS to develop HIV therapy based on LNC platform

CPL-207-280CA demonstrates improved glycemic control and safety in vivo

Amgen discovers new beta-secretase inhibitors

KCNC1/KCNC2 channel modulators presented by Autifony Therapeutics

Pfizer divulges glucagon-like peptide 1 receptor agonists

Cassiopea reports phase III topline results for topical antiandrogen Winlevi for acne

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...